Somewhere in a Huma pitch deck is a slide about "100+ applications on the Huma Cloud Platform," and somewhere else, in a hospital in a country whose regulator has never approved a decentralized clinical trial before, is the person who has to make that slide true. That second person's title is Field CEO. His name is Shayan Khorassani.
Huma is a London digital health company. It calls itself, in the flatly grandiose way that companies with real ambition do, an "AI health infrastructure" platform. Its public-facing summary is a stack: an intelligence layer with analytics and agents on top, a product layer with regulated applications in the middle, and core plumbing at the bottom that connects the fragmented systems hospitals and pharma companies have been arguing with for two decades. The company was founded in 2011, employs around 600 people, and has raised roughly $297 million across several rounds, most recently an $80 million Series D that closed in mid-2024. Its clients are pharma companies, providers, and national health systems, across more than seventy countries. The number of patients on the platform, in the way these numbers are counted, is somewhere around one hundred million.
Which is to say: Huma has scale on paper. The question a "Field CEO" answers is whether scale on paper becomes scale in the world. That job title is a tell. Most companies have a Chief Revenue Officer or a Chief Customer Officer or, if things have gone strange, a Chief Commercial Officer. "Field CEO" implies something more front-of-house. It is the person who behaves like a chief executive when the room is not a boardroom but a hospital procurement office, a ministry of health, a pharma R&D team that needs the platform to do something it does not yet do. Khorassani is that person. Before he was, he was the Deputy Field CEO. Before that, he was an architect.
An unlikely commute
The pivot from architecture to digital health is not obvious. But the more you look at Khorassani's resume the more the logic quietly assembles itself. He earned a Bachelor of Arts from Valencia College, then a Bachelor of Architecture from the Southern California Institute of Architecture - SCI-Arc, in Los Angeles, a school with a reputation for producing designers whose work looks like it belongs in a science-fiction anthology. He worked at Pita & Bloom, at TESTA & WEISER, at Tom Wiscombe Architecture (a studio whose massing models are regularly filed under "extraterrestrial" by the architecture press), and at Connect Homes, a company that ships pre-fabricated modular homes on the back of trucks.
These are, in different registers, all exercises in the same thing: how you take a complicated system and make it buildable under constraint. Modular housing, in particular, is closer to enterprise SaaS than it looks. There is a platform, there are configurations, there are regulators, there are stakeholders who cannot read technical documentation, and there is a delivery date. If you have run a modular home project, you have already run, in miniature, most of what a Field CEO at a healthtech does.
What the job is
Read Huma's own description of itself and you learn that its platform does a lot: remote patient monitoring, perioperative support, decentralized clinical trials, digital companion apps, dashboards, patient-flow management. That list is not a marketing exercise. It is a menu, and Khorassani's job, functionally, is to help a customer look at the menu and order the meal that actually fits their kitchen. This is harder than it sounds. In regulated digital health, every deployment is a small negotiation between what the software can do, what the regulator will allow, what the clinician has time to use, and what the buyer has budgeted. A Field CEO is the person you send in when all four of those constraints are pointed in different directions.
This role becomes even more load-bearing when the company is publicly ambitious. Huma's founder and CEO, Dan Vahdat, has been making the rounds - including, recently, an appearance in Parliament, where he argued for greater investment in British AI and health, with a headline number of roughly £300 billion in potential value. When the CEO is out arguing for national strategy, the field team has to be running the actual work.
The London context
Huma sits at 25 Millbank, a Victorian block on the north bank of the Thames a short walk from the Palace of Westminster. This is not an accident of real estate. London has quietly turned into one of the most concentrated healthtech clusters in the world, and Huma is among its larger residents. The company has raised from an eclectic list of investors - the sort of mixed cap table that includes strategic pharma money alongside more traditional venture. A Series D at the current stage of the cycle is a milestone; it usually implies that the company is expected to keep growing on institutional capital rather than pivot to a strategic exit. The presence of a Field CEO on the org chart, at this stage, reads as a company preparing to run at customer expansion rather than product invention. The product is broadly there. The point is to deploy it.
What we do not know
Khorassani keeps a low public profile. He does not, as far as public sources reveal, run a Substack, tweet often, or turn up on the podcast circuit. His LinkedIn lists a clean pivot from architecture into Huma. His public quotes are minimal. This is, in its own way, informative. Field CEOs of enterprise platforms rarely become media personalities. Their leverage is in showing up prepared to rooms where preparation matters more than volume. The absence of noise is not shyness; it is job description.
The strange specific
What we can say, with some confidence, is that the arc is unusual enough to be worth marking. There are not many Series D health platforms whose Field CEO once helped design a house you ship on a truck. There are not many enterprises whose external commercial face was trained to critique models at SCI-Arc rather than to sell licenses at a Big Four consultancy. This is either an idiosyncratic accident of hiring, or the beginning of a pattern - the healthtech industry finding that people who can sequence a construction project can sequence a hospital deployment, and paying accordingly.
Huma will not be the last regulated software company to figure this out. But it may be one of the first at this scale to put the pattern on its executive page.